Crucell Announces Research License Agreement with ProFibrix on STAR® Technology

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Overig advies 17/12/2007 08:15
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with ProFibrix BV. The license with The Netherlands based ProFibrix covers the production of specific forms of human fibrinogen, a protein involved in haemostasis (blood clotting) and tissue repair. Financial details of the agreement were not disclosed.

About STAR® Technology
STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® technology and the widely used Chinese Hamster Ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements, that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs. STAR® technology was discovered by Dr. Arie Otte (Nature Biotechnology 2003 May 21, (5)) who founded Chromagenics B.V., a spin-off company of the University of Amsterdam, acquired by Crucell in March 2004.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com

About ProFibrix
ProFibrix B.V. is a Dutch biotechnology company that was founded in January 2004 and is located in the Bioscience Park, Leiden, The Netherlands. The company aims to create, develop and market new and innovative healthcare products, based on the unique properties of human fibrinogen. The lead product of the company is FibrocapsTM, a dry powder fibrin sealant based on plasma derived fibrinogen and thrombin that is currently being developed as a topical haemostat for the treatment of severe bleeding during surgery and after trauma injury. ProFibrix is also developing a recombinant manufacturing platform to produce specific variants of fibrinogen for the development of high-added value haemostasis and tissue repair products. The company has developed an extensive network of academic and industrial collaborations that support the R & D activities.



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL